For the clinical trial with immunotherapy, literature demonstrated that avelumab (anti-PD-1) has anti-tumor activity and is safe for patients with GC, which is administered as maintenance therapy (after the disease is under control with standard chemotherapy) (56). Here, PDCD1 is linked to neoplasm.